buoyantintelligence
  • 01Overview
  • 02Portfolio
  • 03Company Atlas
    • Buoyant book
    • All listed companies
  • 04Screener & valuation
  • 05House view
  • 06Markets
  • 07India top-down
  • 08Investors
  • 09Library & data
Release
August 2026 · rev 1
Opportunities PMS · Published
As at 31 Aug 2026 · IST₹ · ₹ cr · BSE 500 TRI
Present
Internal working platform. Published figures are extracted from the August 2026 source package and reviewed; reference prices and fundamentals are unlicensed working data, not for redistribution. Past performance is not indicative of future returns.
All listed companies/Dr. Lal Path Labs Ltd.
03 /Listed universe · Healthcare · Diagnostic Chains

Dr. Lal Path Labs Ltd..

Value itCompareScreener.in ↗Tijori ↗NSE ↗BSE ↗
Snapshot

Healthcare · Diagnostic Chains

Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.

Market cap
₹32,076 cr
P/E (TTM)
59.3
P/B (latest)
12.8
ROE (TTM)
20.1%
ROCE (TTM)
27.7%
Sales CAGR 3y
11.1%
PAT CAGR 3y
28.3%
Debt / equity
0x
Promoter
53.2%
Dividend yield
1.07%
Size
Small
Codes
LALPATHLAB · 539524
Price

₹1,950.4 · 29 Sept 2026

1M
+1.0%
3M
+18.4%
6M
+47.2%
YTD
+29.2%
1Y
+24.5%
3Y
+62.1%
5Y
—
vs 52w high
−0.9%

52-week ₹1,307.6 – ₹1,968.4 · ADTV ₹65.4 cr · price-only.

Trend

Sales and net profit by fiscal year, ₹ crore

Not in the Buoyant book: no house thesis or target is carried. Exchange masters, Tijori and the reference price feed as stated on each tab. All listed companies · NSE EQ